dc.date.accessioned | 2013-03-12T12:34:48Z | |
dc.date.available | 2013-03-12T12:34:48Z | |
dc.date.issued | 2007 | en_US |
dc.date.submitted | 2007-05-30 | en_US |
dc.identifier.citation | Larsen, Camilla Kjellstad, Hetland, Gina Charlotte, . Medikamentell behandling av kronisk systolisk hjertesvikt - er det mulighet for forbedring?. Prosjektoppgave, University of Oslo, 2007 | en_US |
dc.identifier.uri | http://hdl.handle.net/10852/29245 | |
dc.description.abstract | Abstract
Background: Our goal is to review the current treatment recommendations for chronic heart failure (CHF).
Methods: A Medline/PudMed, Cochrane and Google search (1999-2006) was performed using “betablocker AND heart failure”, “ACE-inhibitor AND heart failure”, “Kjekshus”, “Wikstrand” and other pertinent terms.
Results: Beta-blockade should be prescribed for the majority of patients with heart failure, including those over 65 years. Three types of beta-blocker are proven effective; metoprolol CR/XL, bisoprolol and carvedilol. Data suggests that a beta-blocker should be introduced as early as possible. Accordingly to Willenheimer, the CIBIS III trial demonstrated that bisoprolol could be started first just as safely as an ACE inhibitor. ACE-inhibitors should remain first line treatment instead of AII-blockers. An AII-blocker is a good alternative when ACE-inhibitors are not tolerated. The CORONA trial is being performed to determine whether the addition of a statin is beneficial. The standard treatment-regimen for CHF includes ACE-inhibitors, beta-blockers and diuretics, although the treatment with diuretics is not evidence-based. Digitalis should still be used in CHF-patients with atrial fibrillation. In patients with a normal sinus-rhythm, digitalis does not improve survival. Patients with serious CHF (NYHA-class III-IV) should be treated with aldosteron antagonist, but the effect is not yet clear in patients with mild CHF.
Conclusion: Although the treatment guidelines for CHF are well defined, data suggests that the regimen is not always the one used in clinical practice. For example many clinicians use beta-blockers in smaller doses compared to the clinical trials. | nor |
dc.language.iso | nob | en_US |
dc.subject | indremedisin | |
dc.title | Medikamentell behandling av kronisk systolisk hjertesvikt - er det mulighet for forbedring? | en_US |
dc.type | Master thesis | en_US |
dc.date.updated | 2007-08-22 | en_US |
dc.creator.author | Larsen, Camilla Kjellstad | en_US |
dc.creator.author | Hetland, Gina Charlotte | en_US |
dc.subject.nsi | VDP::770 | en_US |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&rft.au=Larsen, Camilla Kjellstad&rft.au=Hetland, Gina Charlotte&rft.title=Medikamentell behandling av kronisk systolisk hjertesvikt - er det mulighet for forbedring?&rft.inst=University of Oslo&rft.date=2007&rft.degree=Prosjektoppgave | en_US |
dc.identifier.urn | URN:NBN:no-15578 | en_US |
dc.type.document | Prosjektoppgave | en_US |
dc.identifier.duo | 60990 | en_US |
dc.contributor.supervisor | Jan Peder Amlie, kardiolog på Rikshospitalet | en_US |
dc.identifier.bibsys | 07116801x | en_US |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/29245/4/Prosjektoppg.Larsen.Hetland.pdf | |